It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Therapeutic Advances:
A large majority of randomized and observational controlled trials of ivermectin are reporting repeated, large magnitude improvements in clinical outcomes. Numerous prophylaxis trials demonstrate that regular ivermectin use leads to large reductions in transmission. Multiple, large “natural experiments” occurred in regions that initiated “ivermectin distribution” campaigns followed by tight, reproducible, temporally associated decreases in case counts and case fatality rates compared with nearby regions without such campaigns.
Conclusions:
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
originally posted by: Phage
Encouraging.
Perhaps they should not have cited Elgazzar though. Hopefully their other sources are more reliable.
R etraction
A large study sponsored by the World Health Organization found that remdesivir doesn’t help hospitalized patients with COVID-19 survive and doesn’t even shorten the recovery time of those who do survive.
But both decisions baffled scientists who have closely watched the clinical trials of remdesivir unfold over the past 6 months—and who have many questions about remdesivir’s worth.
Science has learned that both FDA’s decision and the EU deal came about under unusual circumstances that gave the company important advantages. Many researchers point out that another crucial piece of data is missing entirely from FDA’s statement on remdesivir’s approval: evidence the drug reduces the amount of SARS-CoV-2 in the body, the viral load. “I’ve been working in antivirals for 30 years. Every time you study an antiviral, you show an effect on the virus and you publish it,” says Andrew Hill, a clinical pharmacologist at the University of Liverpool. “Surely Gilead has done that. Where are the data? It is very, very strange.”
The bottom line from the trials so far is there simply isn’t enough evidence that remdesivir works, says Jason Pogue, a University of Michigan, Ann Arbor, researcher who is president of the Society of Infectious Diseases Pharmacists. Pogue believes FDA made a mistake and, unless more data emerge, EMA should not give the drug full approval. “There are more questions than answers about the efficacy of remdesivir in hospitalized patients,” he says.
Therapeutic Advances:
Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19–0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian–Laird method that underpinned the unadjusted analysis. This was also robust against a trial sequential analysis using the Biggerstaff–Tweedie method. Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%).
Conclusions:
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Schwartz said he was very disappointed that the WHO did not support any trial to determine whether the drug could be viable.
“There is a lot of opposition,” he said. “We tried to publish it, and it was kicked away by three journals. No one even wanted to hear about it. You have to ask how come when the world is suffering.”
“This drug will not bring any big economic profits,” and so Big Pharma doesn’t want to deal with it, he said.
Source: joannenova.com.au...
In Peru, Ivermectin cut covid deaths by 75% in 6 weeks: cheap, safe and quite ignored
originally posted by: Phage
a reply to: incoserv
Just so you understand, the Journal did not "recognize" anything.
They published a paper.
How's that?
originally posted by: Phage
a reply to: MykeNukem
In "recognizing" ivermectin they acknowledge it exists. No more, no less.
originally posted by: MykeNukem
originally posted by: Phage
a reply to: MykeNukem
In "recognizing" ivermectin they acknowledge it exists. No more, no less.
Yes, it exists, and this paper they published shows that it has beneficial effects when used as treatment for the Vid.
More than less IMO
originally posted by: Phage
a reply to: incoserv
Just so you understand, the Journal did not "recognize" anything.
They published a paper.
How's that?
originally posted by: Phage
a reply to: incoserv
Just so you understand, the Journal did not "recognize" anything.
They published a paper.
How's that?
originally posted by: SlapMonkey
a reply to: infolurker
Good, so this means that there is an effective treatment, and therefore continuing the use of an EUA-vaccine is illegal.
originally posted by: Phage
a reply to: MykeNukem
They determined that the article was worth publishing. They make no call on the drug. They do not advocate for it, or against it.